These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37402468)

  • 21. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
    Miller KL; Fermaglich LJ; Maynard J
    Orphanet J Rare Dis; 2021 Jun; 16(1):265. PubMed ID: 34107994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed access to treatments for rare diseases: who's to blame?
    Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
    Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The urgent need to empower rare disease organizations in China: an interview-based study.
    Li X; Lu Z; Zhang J; Zhang X; Zhang S; Zhou J; Li B; Ou L
    Orphanet J Rare Dis; 2020 Oct; 15(1):282. PubMed ID: 33046132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets.
    Murthannagari VR; Gonna Nandhi Krishnan G; Manu KV; Jayachandraiah CT; Mandadhi Rajendra PK; Ahmed SS
    Value Health Reg Issues; 2023 May; 35():87-94. PubMed ID: 36921379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience.
    Lomash RM; Shchelochkov O; Chandler RJ; Venditti CP; Pariser AR; Ottinger EA;
    Hum Gene Ther; 2023 Mar; 34(5-6):217-227. PubMed ID: 36694456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
    Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
    Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of orphan designation status for FDA approved drugs, and case studies in oncology, neuroscience and metabolic diseases.
    Brown DG; Wobst HJ
    Bioorg Med Chem; 2023 Feb; 80():117170. PubMed ID: 36696875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review.
    Kacetl J; Marešová P; Maskuriy R; Selamat A
    Risk Manag Healthc Policy; 2020; 13():2125-2148. PubMed ID: 33116992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases.
    Lanar S; Acquadro C; Seaton J; Savre I; Arnould B
    Orphanet J Rare Dis; 2020 Jun; 15(1):134. PubMed ID: 32493385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research advances in pharmacotherapy for rare diseases in children].
    Li JQ; Wang HJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jul; 25(7):759-766. PubMed ID: 37529960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():3-21. PubMed ID: 29214563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
    Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
    Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orphan drug: Development trends and strategies.
    Sharma A; Jacob A; Tandon M; Kumar D
    J Pharm Bioallied Sci; 2010 Oct; 2(4):290-9. PubMed ID: 21180460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.